About Transition Bio
Transition Bio is a company based in Cambridge (United States) founded in 2020 by David A Weitz. Transition Bio has raised $69.27 million across 4 funding rounds from investors including Bristol-Myers Squibb, Northpond Ventures and Taiho Ventures. The company has 9 employees as of December 31, 2021. Transition Bio offers products and services including Condensate Drug Discovery Engine and Microfluidics and AI Engine. Transition Bio operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 9 as on 31 Dec, 2021
- Founders David A Weitz
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Transition Bio Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$69.27 M (USD)
in 4 rounds
-
Latest Funding Round
$13.27 M (USD), Series B
Oct 11, 2024
-
Investors
Bristol-Myers Squibb
& 4 more
-
Employee Count
9
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Transition Bio
Transition Bio offers a comprehensive portfolio of products and services, including Condensate Drug Discovery Engine and Microfluidics and AI Engine.
Platform for analyzing molecular impacts using microfluidics and AI.
System for optimizing chemical matter in drug discovery processes.
People of Transition Bio
Unlock access to complete
Funding Insights of Transition Bio
Transition Bio has successfully raised a total of $69.27M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $13.27 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Transition Bio
Transition Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Northpond Ventures and Taiho Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Taiho Ventures is focused on investing in global biotech ventures.
|
Locked | Locked | Locked | |
|
Magnetic Ventures is focused on transforming healthcare through AI and biotech investments.
|
Locked | Locked | Locked |
Investor details for Transition Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Transition Bio
Investment portfolio details for Transition Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Transition Bio
Detailed financials for Transition Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Transition Bio Comparisons
Peer comparison for Transition Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Transition Bio
Transition Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Transition Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Transition Bio
Complete news archive for Transition Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transition Bio
Transition Bio was founded in 2020.
Transition Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Transition Bio is a funded company, having raised a total of $69.27M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Transition Bio is 9.
Transition Bio was founded in 2020 in Cambridge, United States, within the biotechnology sector. A proprietary platform is developed for analyzing biomolecular condensates, incorporating Condensomics that integrates microfluidic methods and protein biophysics. This technology supports applications in drug discovery and diagnostics, enabling detailed examination of cellular processes. Operations focus on advancing research tools for biomolecular interactions.
Transition Bio's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Transition Bio offers Condensate Drug Discovery Engine and Microfluidics and AI Engine.
Transition Bio has 5 investors. Key investors include Bristol-Myers Squibb, Northpond Ventures, Taiho Ventures, Magnetic Ventures, and Lifeforce Capital.